Company News
- Cyclo Therapeutics Announces Its Publication of the Most Extensive Set of Case Study Reports To-Date on Expanded Access Use of Hydroxypropyl Beta Cyclodextrin in Niemann-Pick Disease Type C
Oct 31, 2019, 8:00 AM EDT - Cyclo Therapeutics Signs Agreement with Worldwide Clinical Trials to Conduct Alzheimer’s Disease Clinical Trial
Oct 30, 2019, 8:00 AM EDT - Cyclo Therapeutics Prepares for Alzheimer’s Development Program After Success with First Patient
Oct 28, 2019, 7:00 AM EDT - Cyclo Therapeutics, Inc. Chief Scientific Officer, Sharon H. Hrynkow, Ph.D., Appointed to President’s Council on Science and Technology
Oct 23, 2019, 8:00 AM EDT - Cyclo Therapeutics Announces Completion of Enrollment in its Phase I Trial to Evaluate Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
Oct 22, 2019, 8:00 AM EDT - Cyclo Therapeutics Announces Its Support for The Firefly Fund’s Newborn Screening Program
Oct 18, 2019, 8:00 AM EDT - Cyclo Therapeutics, Inc. Announces Maurizio Scarpa, MD as EU Coordinating Investigator for the Company’s Pivotal Trial in Niemann-Pick Disease Type C
Oct 9, 2019, 8:00 AM EDT - Cyclo Therapeutics, Inc. – The New Name for CTD Holdings.
Oct 4, 2019, 8:00 AM EDT - CTD Holdings Receives Buy Recommendation from Frazier, Browne and Mayer's Strategic Allocator, a High Net-Worth Investor Journal
Oct 3, 2019, 9:15 AM EDT - CTD Holdings Announces New Collaboration with the Chattanooga Center for Neurologic Research to Advance Alzheimer’s Disease Study
Sep 27, 2019, 10:23 AM EDT
